StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

NATCOPHARM — NATCO PHARMA LTD.

Price History

Data as of 26 Jun 2026· via fincrux

How NATCOPHARM has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Lower end of its 12-month range27% of range

Trading about 25% below its 12-month high — historically cheaper territory for this stock. It sits below its 200-day average, the longer-term trend.

₹790 low₹1,206 high
vs 50-day avg
−13.1%
vs 200-day avg
−2.5%
Beginner mode
Plain English, with everything explained

NATCOPHARM

NSE

NATCO PHARMA LTD.

Healthcare / Pharma

₹903.70
0.00%
last close
0%
Quality Score
Looks high-qualityBig money buying

NATCO PHARMA LTD. clears 3 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹18196.00 Cr
Price tag
14.2×
Money it earns
16.1%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.08goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 16.1%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 22.8%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.[1]NATCO…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What NATCOPHARM owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings400161366275709
Equity Capital3636363636
Reserves4,1554,6665,5567,2988,517
Total Assets4,9785,3886,5548,27010,287
Total Liabilities4,9785,3886,5548,27010,287

Borrowings rising

Total borrowings are up about 77% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for NATCOPHARM — does it earn money consistently?

Consistently profitable

Every one of the last 5 years has been profitable — a sign of durable earnings.

₹139 Cr
₹637 Cr
₹1,307 Cr
₹1,850 Cr
₹1,282 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹1,768 Crrev ₹2,351 Crrev ₹3,569 Crrev ₹4,094 Crrev ₹3,595 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about NATCOPHARM — observations, not recommendations.

Strengths

5
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Profitable in every one of the last 5 years.
  • Sits in the lower part of its 12-month range — historically cheaper territory for this stock.

Risks

0

No notable risks flagged by the numbers right now.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
17.4%+1.9 pp
DII· Domestic institutions
5.5%-0.3 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector